|
TNG462 Clinical Trials
2 actively recruiting trials across 2 locations
▼ -1 trial since May 2026
Pipeline
Phase 1/2: 2
Top Sponsors
- Tango Therapeutics, Inc.2
Indications
- Cancer2
- Liver Disease1
- MTAP Deletion1
- PDAC1
- Thoracic Cancer1
Scottsdale, Arizona1 trial
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Mayo Clinic Scottsdale
Phase 1/2
Palo Alto, California1 trial
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Stanford University
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.